CRCarmine Rossi

Carmine Rossi

*This is an algorithmically generated author record based on publicly available information.

Carmine Rossi has a total of 131 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Treated with External Beam Radiation Therapy Across Different Risk Stratifications in the United States

    by Neal Shore, Benjamin Lowentritt, Charmi Patel, Sabree Burbage, Frederic Kinkead, Carmine Rossi, Francesca Lee, Dominic Pilon, Lawrence Karsh, Gordon Brown

    Background: Despite the availability of several androgen receptor pathway inhibitors for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC), there has been a lack of head-to-head randomized clinical trials to evaluate their comparative efficacy in this population. Objective: This real-world study provides a comprehensive and robust comparison of the decline in prostate-specific antigen ≥90% (PSA90) among patients with mCSPC who initiated apalutamide or abiraterone acetate in the United States. Methods: Clinical data were collected from US community urology practices by Precision Point Specialty Analytics and linked with administrative claims from the Komodo Health Solutions Research Database. Patients with mCSPC were included in apalutamide or abiraterone acetate cohorts based on their first dispensation/paid claim on or after September 17, 2019 (index date), and followed to the earliest of treatment discontinuation or switch, end of insurance/clinical activity, or end of data availability (Dec. 31, 2023). Inverse probability of treatment weighting balanced potentially confounding patient characteristics. PSA90 response by 6 months post index was compared between the cohorts using weighted Kaplan-Meier analysis and time to PSA90 response was compared using a weighted Cox model with a time-varying treatment effect. Results: The study included 1351 patients in the apalutamide cohort and 1003 patients in the abiraterone acetate cohort. By 6 months, 61.4% of the weighted apalutamide cohort and 45.9% of the weighted abiraterone acetate cohort achieved a PSA90 response. Compared with abiraterone acetate, patients treated with apalutamide were 73% more likely to achieve a PSA90 response at 6 months (weighted hazard ratio, 1.73; 95% confidence interval, 1.44-2.08; P < .001). The median time to PSA90 response was 3.8 and 8.7 months in the apalutamide and abiraterone acetate cohorts, respectively. Conclusions: The results of this study confirm that patients with mCSPC treated with apalutamide have significantly higher rates of PSA90 response compared with abiraterone acetate after 6 months of treatment. Real-world evidence highlights apalutamide as an important treatment option to improve the prognosis of patients with mCSPC.

  • Open Access

    Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Treated with External Beam Radiation Therapy Across Different Risk Stratifications in the United States

    by Neal Shore, Benjamin Lowentritt, Charmi Patel, Sabree Burbage, Frederic Kinkead, Carmine Rossi, Francesca Lee, Dominic Pilon, Lawrence Karsh, Gordon Brown

    Background: External beam radiation therapy (EBRT) is an effective treatment option for patients with localized prostate cancer (LPC). Despite the widespread use of EBRT, evaluation of outcomes based on LPC risk status is limited. Objectives: To comprehensively compare clinical and economic outcomes between patients with high-risk vs low/intermediate-risk LPC following EBRT in real-world United States (US) clinical practice. Methods: This retrospective study used linked patient-level electronic medical record data from PPS Analytics and administrative claims data from the Komodo Research Database (1 January 2016–31 August 2024). Patients with LPC treated with EBRT (date of the first claim was defined as the index date) were identified and stratified into high-risk and low/intermediate-risk cohorts based on clinical guidelines incorporating information based on localized cancer staging, Gleason score, and prostate-specific antigen level. Baseline characteristics were balanced using inverse probability of treatment weighting. A weighted Cox proportional hazards model was used to compare metastasis-free survival (MFS) and event-free survival (EFS) between cohorts. Weighted ordinary least squares regression was used to compare all-cause and PC-related healthcare costs (2024 US dollars), measured per-patient-per-year (PPPY), in the subgroup of patients with continuous insurance eligibility. Results: In total, 5984 and 10 471 patients were included in the high-risk and low/intermediate-risk LPC cohorts, respectively. Patients with low/intermediate-risk vs high-risk LPC had significantly longer MFS (36-month hazard ratio [HR]; 95% confidence interval [CI]: 2.47 [2.15, 2.84], P < .001; 60-month HR: 2.29 [2.05, 2.55], P < .001) and EFS (36-month HR: 1.84 [1.65, 2.06], P < .001; 60-month HR: 1.90 [1.73, 2.08], P < .001). Among the subgroup of patients with continuous insurance eligibility (high-risk: 980 patients; low/intermediate-risk: 1862 patients), patients with high-risk LPC incurred significantly higher mean total all-cause healthcare costs (cost difference [95% CI]: $8269 PPPY [3869, 12 800], P < .001) and mean total PC-related healthcare costs ($9053 PPPY [5232, 13 147], P < .001) post-index compared with those with low/intermediate-risk LPC. Conclusion: Patients with high-risk vs low/intermediate-risk LPC had significantly worse survival outcomes and incurred significantly higher costs following EBRT, consistent with the greater disease burden associated with high-risk disease. More effective treatment strategies are needed to further improve clinical outcomes and reduce economic burden among this patient population.

  • Open Access

    Real-World Clinical and Economic Outcomes Among Patients With Localized Prostate Cancer Treated With External Beam Radiation Therapy Across Different Risk Stratifications in the United States

    by Neal Shore, Benjamin Lowentritt, Charmi Patel, Sabree Burbage, Frederic Kinkead, Carmine Rossi, Francesca Lee, Dominic Pilon, Lawrence Karsh, Gordon Brown

    Background: External beam radiation therapy (EBRT) is an effective treatment option for patients with localized prostate cancer (LPC). Despite the widespread use of EBRT, evaluation of outcomes based on LPC risk status is limited. Objectives: To comprehensively compare clinical and economic outcomes between patients with high-risk vs low/intermediate-risk LPC following EBRT in real-world United States (US) clinical practice. Methods: This retrospective study used linked patient-level electronic medical record data from PPS Analytics and administrative claims data from the Komodo Research Database (1 January 2016–31 August 2024). Patients with LPC treated with EBRT (date of the first claim was defined as the index date) were identified and stratified into high-risk and low/intermediate-risk cohorts based on clinical guidelines incorporating information based on localized cancer staging, Gleason score, and prostate-specific antigen level. Baseline characteristics were balanced using inverse probability of treatment weighting. A weighted Cox proportional hazards model was used to compare metastasis-free survival (MFS) and event-free survival (EFS) between cohorts. Weighted ordinary least squares regression was used to compare all-cause and PC-related healthcare costs (2024 US dollars), measured per-patient-per-year (PPPY), in the subgroup of patients with continuous insurance eligibility. Results: In total, 5984 and 10 471 patients were included in the high-risk and low/intermediate-risk LPC cohorts, respectively. Patients with low/intermediate-risk vs high-risk LPC had significantly longer MFS (36-month hazard ratio [HR]; 95% confidence interval [CI]: 2.47 [2.15, 2.84], P < .001; 60-month HR: 2.29 [2.05, 2.55], P < .001) and EFS (36-month HR: 1.84 [1.65, 2.06], P < .001; 60-month HR: 1.90 [1.73, 2.08], P < .001). Among the subgroup of patients with continuous insurance eligibility (high-risk: 980 patients; low/intermediate-risk: 1862 patients), patients with high-risk LPC incurred significantly higher mean total all-cause healthcare costs (cost difference [95% CI]: $8269 PPPY [3869, 12 800], P < .001) and mean total PC-related healthcare costs ($9053 PPPY [5232, 13 147], P < .001) post-index compared with those with low/intermediate-risk LPC. Conclusion: Patients with high-risk vs low/intermediate-risk LPC had significantly worse survival outcomes and incurred significantly higher costs following EBRT, consistent with the greater disease burden associated with high-risk disease. More effective treatment strategies are needed to further improve clinical outcomes and reduce economic burden among this patient population.

  • Open Access

    Real-World PSA Response and Overall Survival Among Men with mCSPC Receiving Apalutamide Versus Darolutamide (Both Without Docetaxel) in the US

    by Mehmet A. Bilen, Gordon Brown, Mukul Singhal, Carmine Rossi, Dominic Pilon, Courtney D. Longfield, Benjamin Lowentritt

  • Open Access

    Real-world comparative effectiveness of apalutamide versus enzalutamide for prostate-specific antigen response in metastatic castration-sensitive prostate cancer

    by Mehmet A. Bilen, Benjamin H. Lowentritt, Sabree Burbage, Charmi Patel, Carmine Rossi, Frederic Kinkead, Gordon Wong, Dominic Pilon, Neal D. Shore

    Background: Deep and rapid prostate-specific antigen (PSA) response is an important indicator to consider in treatment decision-making given its predictive value for long-term clinical outcomes in metastatic castration-sensitive prostate cancer (mCSPC). Objectives: This study compared early PSA90 response (⩾90% reduction in PSA levels) in a large and recent cohort of patients with mCSPC initiating apalutamide or enzalutamide in the United States. Design: A retrospective longitudinal analysis was conducted. Methods: Patients with mCSPC were identified from linked claims and electronic medical record data from the United States and categorized into the apalutamide or enzalutamide cohorts based on the first claim/dispensation on or after December 16th, 2019. To adjust for differences observed in patient characteristics between the two cohorts, inverse probability of treatment weighting was used. Weighted Cox proportional hazards models were used to compare PSA90 response (PSA measurement ⩾90% lower than the most recent pretreatment PSA value) by 6 months post treatment initiation between the apalutamide and enzalutamide cohorts. Results: Among 1296 patients with mCSPC treated with apalutamide and 1111 treated with enzalutamide, pretreatment characteristics were balanced after weighting. PSA90 response by 6 months was achieved by 61.7% of patients in the apalutamide cohort and 55.2% of patients in the enzalutamide cohort (weighted hazard ratio: 1.20 [95% confidence interval: 1.07, 1.36]; p = 0.003). Patients in the apalutamide cohort achieved a PSA90 response earlier than those in the enzalutamide cohort (median time to PSA90 response: 3.7 vs 4.9 months, respectively). Conclusion: In a large, real-world, retrospective analysis, patients with mCSPC treated with apalutamide were associated with a significantly higher rate of early PSA90 response compared to enzalutamide.

  • Open Access

    Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Undergoing Radical Prostatectomy Across Different Risk Stratifications in the United States

    by Neal Shore, Benjamin Lowentritt, Charmi Patel, Sabree Burbage, Frederic Kinkead, Carmine Rossi, Francesca Lee, Dominic Pilon, Lawrence Karsh, Gordon Brown

    Radical prostatectomy is a potentially curative treatment for localized prostate cancer (LPC), but there is limited literature comprehensively describing clinical and economic outcomes stratified by risk group. This study compared survival and healthcare costs following radical prostatectomy between patients with high-risk and low/intermediate-risk LPC in routine urology practice in the US. Linked electronic medical records and administrative claims were used to identify men with LPC undergoing radical prostatectomy (index date). Patients were classified into high-risk or low/intermediate-risk cohorts based on staging, prostate-specific antigen test results, and Gleason score, in alignment with the National Comprehensive Cancer Network®. Cohorts were balanced using inverse probability of treatment weighting. Metastasis-free survival and event-free survival post index were compared between cohorts using a weighted Cox proportional hazards model. All-cause/prostate cancer (PC)-related healthcare costs were compared post index using weighted ordinary least squares regression in a subgroup of patients with 12 months of continuous insurance eligibility prior to/including index. Patients in the high-risk cohort (N=7542) had significantly higher rates of metastasis (36 months: hazard ratio [95% confidence interval (CI)]: 3.80 [3.31, 4.38], p<0.001; 60 months: 3.59 [3.19, 4.04], p<0.001) and disease progression (36 months: 3.49 [3.28, 3.71], p<0.001; 60 months: 3.37 [3.18, 3.57], p<0.001) compared to patients in the low/intermediate-risk cohort (N=11,429). In the cost subgroup, the high-risk cohort (N=1488) incurred significantly higher mean total all-cause healthcare costs (cost difference [95% CI]: $9134 [5999, 12,400] per-patient-per-year, p<0.001) and mean total PC-related healthcare costs ($7502 [4718, 10,279] per-patient-per-year, p<0.001) compared to the low/intermediate-risk cohort (N=2572) post index. In this real-world analysis of patients with LPC who underwent radical prostatectomy, high-risk disease was significantly associated with poorer survival and higher healthcare costs post-procedure compared to low/intermediate-risk LPC. These findings demonstrate the heightened clinical and economic burden observed with high-risk LPC.

  • Open Access

    Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide

    by Benjamin H Lowentritt, Sabree Burbage, Ibrahim Khilfeh, Dominic Pilon, Shawn Du, Carmine Rossi, Frederic Kinkead, Lilian Diaz, Gordon Brown

    Aim: There is limited real-world evidence about prostate-specific antigen (PSA) response to androgen receptor pathway inhibitor treatment in Black patients with metastatic castration-sensitive prostate cancer (mCSPC). This study compared PSA90 (≥90% reduction from baseline PSA level) between apalutamide and enzalutamide among Black patients with mCSPC. Materials & methods: Electronic medical record data (Precision Point Specialty Analytics) were linked to claims data (Komodo Research Database) and used to select cohorts of Black patients with mCSPC treated with either apalutamide or enzalutamide. Inverse probability of treatment weighting was used to balance treatment cohorts. PSA90 response was assessed using weighted Kaplan–Meier curves and hazard ratios with 95% CIs. Results: The study included 451 patients (apalutamide: 230, enzalutamide: 221) with balanced baseline characteristics after inverse probability of treatment weighting. Patients treated with apalutamide had a 42% higher rate of PSA90 response within 6 months post-index compared with those treated with enzalutamide (hazard ratio: 1.42, 95% CI: 1.06, 1.91; p = 0.020). Median time to first PSA90 response was shorter among patients treated with apalutamide (3.3 months) compared with enzalutamide (5.5 months). Conclusion: In Black patients with mCSPC, apalutamide led to faster and significantly deeper PSA responses than enzalutamide, suggesting potential clinical advantages in optimizing early treatment response in this population. Future research should assess PSA90 as a prognostic indicator of overall survival among Black patients.


  • Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer

    by Mehmet A. Bilen, Neal Shore, Sabree Burbage, Carmine Rossi, Lilian Diaz, Ibrahim Khilfeh, Yuxi Wang, Gordon Wong, Dominic Pilon, Gordon Brown, et al.


  • Open Access

    Comparison of Prostate-Specific Antigen Response in Black Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide vs Abiraterone Acetate

    by Gordon Brown, Sabree Burbage, Ibrahim Khilfeh, Carmine Rossi, Shawn Du, Frederic Kinkead, Lilian Diaz, Dominic Pilon, Benjamin Lowentritt

    Background: Improved clinical outcomes have been observed in patients with metastatic castration-sensitive prostate cancer (mCSPC) who experience deep prostate-specific antigen (PSA) responses after treatment with androgen receptor pathway inhibitors (ARPIs). Objective: This retrospective longitudinal study aimed to compare real-world PSA90 response (≥90% reduction from pretreatment levels) in Black patients with mCSPC treated with apalutamide vs abiraterone acetate. Methods: Electronic medical record (EMR) data from Precision Point Specialty Analytics were linked to claims data from the Komodo Research Database. Black adult patients with mCSPC who initiated apalutamide or abiraterone acetate on or after 9/17/2019 were included. Inverse probability of treatment weighting was used to balance patient characteristics between treatment cohorts. PSA90 was evaluated during the on-treatment period, defined as the time from index date to the earliest of treatment discontinuation, initiation of a new ARPI or radiopharmaceutical, or end of insurance claims activity or clinical activity. Weighted Kaplan-Meier curves and hazard ratios (HRs) were used to compare PSA90 responses between treatment cohorts. Results: This study included 363 patients, of which 236 initiated apalutamide and 127 initiated abiraterone acetate. At 6 months following treatment initiation, a greater proportion of patients treated with apalutamide (65.4%) vs abiraterone acetate (49.0%) achieved a PSA90 response. Patients who initiated apalutamide vs abiraterone acetate were 66% more likely to achieve a PSA90 response within 6 months of treatment initiation (HR, 1.66; 95% confidence interval, 1.18-2.35; P = .004). The median time-to-PSA90 response was approximately 6 months earlier for patients treated with apalutamide (3.3 months) compared with abiraterone acetate (9.1 months). Discussion: This study leveraged robust information from combined insurance claims and routinely collected EMR data to evaluate PSA90, a clinically relevant biomarker of treatment response, among Black patients with mCSPC. These results are among the first in this understudied patient population and suggest that a deeper and earlier PSA response achieved with apalutamide relative to abiraterone acetate can extend to Black patients in a real-world US clinical setting. Conclusion: Black patients treated with apalutamide experienced significantly higher PSA90 response rates than those treated with abiraterone acetate, suggesting possible clinical benefits from early treatment response in this population.


  • Open Access

    Comparison of Prostate-Specific Antigen Response in Black Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide vs Abiraterone Acetate

    by Gordon Brown, Sabree Burbage, Ibrahim Khilfeh, Carmine Rossi, Shawn Du, Frederic Kinkead, Lilian Diaz, Dominic Pilon, Benjamin Lowentritt

    Background: Improved clinical outcomes have been observed in patients with metastatic castration-sensitive prostate cancer (mCSPC) who experience deep prostate-specific antigen (PSA) responses after treatment with androgen receptor pathway inhibitors (ARPIs). Objective: This retrospective longitudinal study aimed to compare real-world PSA90 response (≥90% reduction from pretreatment levels) in Black patients with mCSPC treated with apalutamide vs abiraterone acetate. Methods: Electronic medical record (EMR) data from Precision Point Specialty Analytics were linked to claims data from the Komodo Research Database. Black adult patients with mCSPC who initiated apalutamide or abiraterone acetate on or after 9/17/2019 were included. Inverse probability of treatment weighting was used to balance patient characteristics between treatment cohorts. PSA90 was evaluated during the on-treatment period, defined as the time from index date to the earliest of treatment discontinuation, initiation of a new ARPI or radiopharmaceutical, or end of insurance claims activity or clinical activity. Weighted Kaplan-Meier curves and hazard ratios (HRs) were used to compare PSA90 responses between treatment cohorts. Results: This study included 363 patients, of which 236 initiated apalutamide and 127 initiated abiraterone acetate. At 6 months following treatment initiation, a greater proportion of patients treated with apalutamide (65.4%) vs abiraterone acetate (49.0%) achieved a PSA90 response. Patients who initiated apalutamide vs abiraterone acetate were 66% more likely to achieve a PSA90 response within 6 months of treatment initiation (HR, 1.66; 95% confidence interval, 1.18-2.35; P = .004). The median time-to-PSA90 response was approximately 6 months earlier for patients treated with apalutamide (3.3 months) compared with abiraterone acetate (9.1 months). Discussion: This study leveraged robust information from combined insurance claims and routinely collected EMR data to evaluate PSA90, a clinically relevant biomarker of treatment response, among Black patients with mCSPC. These results are among the first in this understudied patient population and suggest that a deeper and earlier PSA response achieved with apalutamide relative to abiraterone acetate can extend to Black patients in a real-world US clinical setting. Conclusion: Black patients treated with apalutamide experienced significantly higher PSA90 response rates than those treated with abiraterone acetate, suggesting possible clinical benefits from early treatment response in this population.